Treatment of asthmatic patients with a cysteinyl leukotriene receptor‐1 antagonist montelukast (Singulair), decreases the eosinophil survival‐enhancing activity produced by peripheral blood mononuclear leukocytes in vitro [PDF]
K. Becler, Lena Håkansson, S. Rak
openalex +1 more source
Aspirin desensitisation therapy for aspirin-intolerant chronic rhinosinusitis [PDF]
Lipworth, Brian J.+2 more
core +2 more sources
Improvement of Cold Urticaria by Treatment with the Leukotriene Receptor Antagonist Montelukast
Karin Hartmann
openalex +1 more source
Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs [PDF]
David A. Stempel+2 more
openalex +1 more source
Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy [PDF]
JC Virchow
openalex +1 more source
Montelukast, an approved leukotriene receptor 1 (Cys-LT 1) antagonist with anti-inflammatory properties is used for the treatment of asthma and allergic rhinitis. In the present studies, montelukast was subjected to in vitro inhibitory assays followed by
Shawana Abdullah+8 more
doaj
Montelukast in asthma treatment in Croatia.
The aim of this study was to determine the efficacy and safety of montelukast added to previous medication in the treatment of a mild and moderate asthma. Data were obtained via questionnaires given to the physicians and given further to their patients.
Samaržija, M.+5 more
openaire +2 more sources
Montelukast Improves Urinary Bladder Function After Complete Spinal Cord Injury in Rats. [PDF]
Keller EE+8 more
europepmc +1 more source
Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis. [PDF]
Mahmood SF+5 more
europepmc +1 more source